Medical Outsourcing in Calgary Canada
Medical Outsourcing in Calgary section, includes general infrmation about Medical Outsourcing Procedure, Medical Outsourcing Calgary Local News, Medical Outsourcing Calgary Surgeon Locator and other Medical Outsourcing related material.
Medical Outsourcing Procedure
Medical Outsourcing can be defined as a health holiday. These patients going to a different country for either urgent or elective medical procedures is becoming a worldwide, multibillion-dollar industry. Medical Outsourcing is ‘cost effective’ private medical care in collaboration with the tourism industry for patients needing surgical and/or other forms of specialized treatment.
Medical Outsourcing combines wellness and healthcare alongside leisure and relaxation. Medical Outsourcing is aimed at rejuvenating a person; mentally, physically and emotionally. It involves the idea of drawing you away from your daily routine to a relaxed surrounding in an exotic location. Many medical outsourcing tourists are seeking treatment at a quarter or sometimes even a 10th of the cost at home. These patients are often people who are frustrated by long waiting times. Becoming a medical outsourcing tourist is a chance to combine a tropical vacation with elective or plastic surgery.
Countries that actively promote Medical Outsourcing include Cuba, Costa Rica, Hungary, India, Israel, Jordan, Lithuania, Malaysia and Thailand. Belgium, Poland and Singapore are now entering the field. South Africa specializes in medical safaris-visit the country for a safari, with a stopover for plastic surgery, a nose job and a chance to see lions and elephants.
Research is the first step to successful medical outsourcing travel. Make sure that you do your research on the following:
The Procedure: Find out about the procedure and compare your expectations with what is achievable by the surgery. Also inquire about follow-up care needed, time required for recovery, physical therapy, etc.
The Hospital: When selecting the hospital that is right for your needs, you should consider the hospital's accreditation, awards and recognitions, facility and equipments, statistics like success rates, etc.
The Surgeon: Check the certifications, training and repute of the surgeon who will be treating you.
The Destination Country: You should base your selection on quality, distance and cost.
Always work with your local doctor and inform him about your decision to travel overseas for treatment. You may need his assistance prior to the surgery for furnishing the health records required by the international hospital and post surgery for any follow-up checks that may be required.
More Calgary info...
Calgary By car
This is essentially the prairies; crossing the vast expanses in the comfort of your own vehicle is the main method of transportation. Calgary is just over an hour's drive East of Banff (on the Transcanada highway, #1), and about 3 hours South of Edmonton on highway #2. From the USA side, use the I-15 Fwy. Calgary is about 200 miles (320 km) north of the border. It is likely that you will want to rent a car to explore Calgary and its surroundings.
-
Calgary Eat
Calgary offers a wide variety of dining options. While Calgary doesn't have a single signature dish, residents are very proud of Alberta Beef, and Calgarians are discerning clients of steakhouses. Speaking of beef, the popular Chinese-Canadian dish of ginger beef was invented in Calgary in the 1970s. Calgary is also home to a very culturally diverse population, with a very wide selection of international restaurants, especially from East and Southeast Asia, and the Mediterranean from Italy through Lebanon. Calgary is, however, generally lacking in decent Mexican food, and the inland location means that a good meal of seafood is sometimes hard to find.
-
Plastic Surgery News...
- According to research published in the Journal of the American Medical Association, there were no significant differences in clinical outcomes between patients receiving sirolimus- and paclitaxel-eluting stents in everyday clinical practice.
Researchers evaluated sirolimus- and paclitaxel-eluting stents for the prevention of symptom-driven clinical end points, using a study design reflecting everyday clinical practice. The SORT OUT II trial involved 2098 patients treated with percutaneous coronary intervention (PCI) and randomised to receive either sirolimus-eluting (n = 1065) or paclitaxel-eluting (n = 1033) stents. Indications for PCI included ST-segment elevation myocardial infarction (STEMI), non-STEMI or unstable angina pectoris, and stable angina. Additionally, dual antiplatelet therapy with aspirin and clopidogrel was recommended for 1 year for all patients. After that period, clopidogrel was discontinued and aspirin continued lifelong, if tolerated.
The primary end point was a composite clinical end point of major adverse cardiac events, defined as either cardiac death, acute myocardial infarction, target lesion revascularisation, or target vessel revascularisation. Secondary end points were individual components of the composite end point, all-cause mortality and stent thrombosis.
The following results were reported:
• With respect to the primary end point, the sirolimus- and the paclitaxel-eluting stent groups did not differ significantly in major adverse cardiac events (98 [9.3%] vs. 114 [11.2%]; hazard ratio, 0.83 [95% confidence interval, 0.63-1.08]; P = 0.16)
• Additionally, no statistically significant differences were reported in stent thrombosis rates, rates of acute myocardial infarction, target lesion or vessel revascularisation, cardiac death or all-cause death
In a related editorial, the authors comment on possible limitations of the study:
1. The study randomised less than a third of the potentially eligible patients, which suggests that the cohort may not be as unselected as the authors had intended for emulating real life practice
2. The study was underpowered due to the small sample size coupled with relatively low event rates
- Abstract Surgical management of facial hemangiomas, the most common childhood neoplasms and infiltrating facial vascular malformations,
has the risk of injury to the facial nerve and remains controversial. The aim of this study was to analyze the use of the
commercially available Neurosign 100® Nerve Monitor in those cases of facial vascular anomalies where resection was considered
the appropriate treatment. On a prospective basis, six consecutive patients with deep (so-called infiltrating) vascular anomalies
of the face (two hemangiomas, three lymphatic malformation, one lymphatico-venous malformation) were enrolled in this study.
During surgical preparation, electromyographic (EMG) activity of the muscles innervated by the facial nerve was monitored.
The variables collected included the patient’s sex, age at surgery, location of the lesion and depth, prior treatment, diagnostic
workup, site of skin incision, operating time, operative and postoperative complications, and reconstructive outcome. All
lesions were resected without major bleeding. Postoperatively, all patients showed regular, symmetrical function of the facial
nerve. The mean operating time was 136.7 min (range 90 to 240 min). During the preparation using surgical instruments, EMG
activity was noted both as a graphic signal showing facial nerve activity and as an acoustic signal. In all patients, the
branches of the facial nerve were identified clinically by electrode stimulation at 30 Hz. Postoperatively, all patients had
improvement of facial asymmetry and deformity; preoperative pain episodes and functional impairments resolved completely.
Intraoperative facial nerve monitoring provides feedback regarding the location, extent, and ongoing functional status of
the facial nerve in the surgical management of infiltrating benign lesions such as hemangiomas and vascular malformations.
Besides an overall distinct indication for surgery, we recommend its use for prevention of iatrogenic facial nerve injury.
Content Type Journal ArticleCategory Original PaperDOI 10.1007/s00238-008-0224-4Authors
H. Kubiena, Medical University of Vienna Division of Plastic and Reconstructive Surgery, Department of Surgery Waehringerguertel, 18-20 Vienna 1090 AustriaJ. Roka, Medical University of Vienna Division of Plastic and Reconstructive Surgery, Department of Surgery Waehringerguertel, 18-20 Vienna 1090 AustriaM. Frey, Medical University of Vienna Division of Plastic and Reconstructive Surgery, Department of Surgery Waehringerguertel, 18-20 Vienna 1090 Austria
Journal European Journal of Plastic SurgeryOnline ISSN 1435-0130Print ISSN 0930-343X (Source: European Journal of Plastic Surgery)